



Fig. S5. MDSC isolated from the tumors of mice treated with DC.IL32 retain immune suppressor function. MLR were established using MACS CD4⁺CD25^{neg} BALB/c splenocytes (pre-labeled with CFSE) and C57BL/6 DC.null stimulator cells as described in Materials and Methods. As indicated, flow-sorted CD11b⁺Gr1⁺ MDSC isolated from day 21 tumors harvested from mice treated (per Fig. 5A) with i.t. DC.IL32 or control DC were added at the indicated MDSC-to-responder CD4⁺ T cell ratios. **A**, after a 72h incubation period, CD4⁺ T cell proliferation was analyzed based on CFSE dilution as monitored by flow cytometry as described in Materials and Methods. **B**, the percentage of control (no MDSC) CD4⁺ T cell proliferation is reported. All inter-group differences were not significant. Data are from 1 representative experiment of 3 performed.